Phase II Study of Panitumumab Monotherapy in Chemotherapy-Naïve Frail or Elderly Patients with Unresectable <i>RAS</i> Wild-Type Colorectal Cancer: OGSG 1602Tetsuji Terazawa, Taroh Satoh, Tatsushi Shingai et al.|The Oncologist|2020Cited by 19
Randomized phase II study of S-1 dosing schedule for resected colorectal cancerChu Matsuda, Masaki Mori, Mamoru Uemura et al.|BMC Cancer|2015Cited by 2
Phase II study of panitumumab monotherapy in chemotherapy-naïve frail or elderly patients with unresectable, <i>RAS</i> wild-type colorectal cancer: OGSG 1602.Katsuya Ohta, Takeshi Kato, Masahiro Goto et al.|Journal of Clinical Oncology|2020Cited by 2
The Phase II Study of Panitumumab in Chemotherapy-Naïve Frail or Elderly Patients with <i>RAS</i> Wild-type Colorectal Cancer: OGSG 1602 Final ResultsTetsuji Terazawa, Taroh Satoh, Takeshi Kato et al.|The Oncologist|2022Cited by 2
P-76 Phase II study of FOLFIRI plus ramucirumab with recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin/fluoropyrimidine (RAINCLOUD)N. Sugimoto, Hiroshi Eguchi, Ken Nakata et al.|Annals of Oncology|2022Cited by 1